Table 1.
Demographic, Clinical, and Laboratory Data
| HV (n = 15) | EH (n = 15) | RVH (n = 15) | P | |
|---|---|---|---|---|
| Age, y | 71.9 ± 5.7 | 67.0 ± 7.4 | 69.2 ± 7.4 | 0.1 for trend |
| Men | 5 (33) | 9 (60) | 10 (67) | 0.1 for trend |
| BMI, kg/m2 | 26.2 ± 6.2 | 28.5 ± 3.6 | 27.8 ± 4.2 | 0.4 for trend |
| Systolic BP, mm Hg | 117.3 ± 5.9 | 132.0 ± 17.8 | 140.7 ± 18.0 | <0.001 for trend; 0.2 (RVH vs EH); <0.001 (RVH vs HV), 0.02 (EH vs HV) |
| Diastolic BP, mm Hg | 71.9 ± 5.9 | 71.6 ± 13.7 | 69.0 ± 9.4 | 0.7 for trend |
| No. of anti-HTN drugs | — | 2.8 ± 1.0 | 3.0 ± 1.2 | 0.6 (RVH vs EH) |
| ARB or ACEi | 15 (100) | 15 (100) | ||
| CCB | 5 (33) | 7 (47) | 0.5 (RVH vs EH) | |
| β-Blocker | 7 (47) | 11 (73) | 0.1 (RVH vs EH) | |
| Diuretics | 13 (87) | 11 (73) | 0.4 (RVH vs EH) | |
| Statins | 8 (53) | 10 (67) | 0.5 (RVH vs EH) | |
| Total cholesterol, mg/dL | 202.4 ± 31.9 | 179.3 ± 34.0 | 180.0 ± 31.1 | 0.1 for trend |
| Triglycerides, mg/dL | 100.4 ± 38.5 | 141.4 ± 65.5 | 158.0 ± 74 | 0.05 for trend; 0.2 (RVH vs EH); 0.04 (RVH vs HV); 0.8 (EH vs HV) |
| HDL, mg/dL | 70.8 ± 28.7 | 48.4 ± 12.6 | 51.8 ± 23.0 | 0.02 for trend; 0.9 (RVH vs EH); 0.08 (RVH vs HV); 0.02 (EH vs HV) |
| LDL, mg/dL | 110.9 ± 23.9 | 102.6 ± 24.0 | 96.6 ± 21.6 | 0.3 for trend |
| eGFR, mL/min/1.73 m2 | 72.0 ± 15.9 | 73.3 ± 22.0 | 50.3 ± 17.3 | 0.002 for trend; 0.004 (RVH vs EH); 0.007 (RVH vs HV); 0.9 (EH vs HV) |
| Albuminuria, μg/mL | 4.1 [2.2–5.8] | 5.0 [4.8–7.8] | 5.3 [4.9–9.5] | 0.4 for trend |
Note: Values for normally distributed continuous variables given as mean ± SD, non-normally distributed, as median [interquartile range]; categorical variables, as no. (%).
Abbreviations: ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; BMI, body mass index; BP, blood pressure; CCB, calcium channel blocker; eGFR, estimated glomerular filtration rate; HDL, high-density lipoprotein cholesterol; HTN, hypertension; LDL, low-density lipoprotein cholesterol.